CD10 is inversely associated with nuclear factor-kappa B and predicts biochemical recurrence after radical prostatectomy

Urologia Internationalis

Volumn 88, Issue 2, 2012, Pages 158-164

  Voutsadakis, Ioannis A ^a,b   Vlachostergios, Panagiotis J ^a   Daliani, Danai D ^a   Karasavvidou, Foteini ^a   Kakkas, Grigorios ^a   Moutzouris, George ^a   Melekos, Michael D ^a   Papandreou, Christos N ^a  

^a UNIVERSITY HOSPITAL OF LARISSA   (Greece)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

CD10; Nuclear factor B; Prostate cancer; Prostate specific antigen relapse

Indexed keywords

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NEUROPEPTIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER LOCALIZATION; CANCER RELAPSE; CANCER STAGING; CHEMICAL ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; GLEASON SCORE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION;

AGED; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOWN-REGULATION; GREECE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEPRILYSIN; NF-KAPPA B; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT FAILURE; UP-REGULATION;

EID: 84859422967     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000335299     Document Type: Article

References (23)

1. Nelson J, Bagnato A, Battistini B, Nisen P: The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003; 3: 110-116. (Pubitemid 37328878)
2. Sumitomo M, Shen R, Nanus DM: Involvement of neutral endopeptidase in neoplastic progression. Biochim Biophys Acta 2005; 1751: 52-59. (Pubitemid 41033294)
3. Papandreou CN, Usmani B, Geng Y, Bogenrieder T, Freeman R, Wilk S, Finstad CL, Reuter VE, Powell CT, Scheinberg D, Magill C, Scher HI, Albino AP, Nanus DM: Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med 1998; 4: 50-57. (Pubitemid 28133079)
4. Osman I, Yee H, Taneja SS, Levinson B, Zeleniuch-Jacquotte A, Chang C, Nobert C, Nanus DM: Neutral endopeptidase protein expression and prognosis in localized prostate cancer. Clin Cancer Res 2004; 10: 4096-4100. (Pubitemid 38812488)
5. Dall'Era MA, True LD, Siegel AF, Porter MP, Sherertz TM, Liu AY: Differential expression of CD10 in prostate cancer and its clinical implication. BMC Urol 2007; 7: 3-13.
6. Fleischmann A, Schlomm T, Huland H, Kollermann J, Simon P, Mirlacher M, Salomon G, Chun FH, Steuber T, Simon R, Sauter G, Graefen M, Erbersdobler A: Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients. Clin Cancer Res 2008; 14: 7838-7842.
7. Jin RJ, Lho Y, Connelly L, Wang Y, Yu X, Saint Jean L, Case TC, Ellwood-Yen K, Sawyers CL, Bhowmick NA, Blackwell TS, Yull FE, Matusik RJ: The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Res 2008; 68: 6762-6769.
8. Koumakpayi IH, Le Page C, Mes-Masson A-M, Saad F: Hierarchical clustering of immunohistochemical analysis of the activated ErbB/PI3K/Akt/NF-kappaB signaling pathway and prognostic significance in prostate cancer. Br J Cancer 2010; 102: 1163-1173.
9. Domingo-Domenech J, Mellado B, Ferrer B, Truan D, Codony-Servat J, Sauleda S, Alcover J, Campo E, Gascon P, Rovira A, Ross JS, Fernandez PL, Albanell J: Activation of nuclear factor-B in human prostate carcinogenesis and association to biochemical relapse. Br J Cancer 2005; 93: 1285-1294.
10. Epstein JI, Amin M, Boccon-Gibod L, Egevad L, Humphrey PA, Mikuz G, Newling D, Nilsson S, Sakr W, Srigley JR, Wheeler TM, Montironi R: Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Scand J Urol Nephrol Suppl 2005; 216: 34-63.
11. Scher HI, Sawyers CL: Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005; 32: 8253-8261. (Pubitemid 46211563)
12. Voutsadakis IA, Papandreou CN: The ubiquitin-proteasome system in prostate cancer and its transition to castration resistance. Urol Oncol 2010, Epub ahead of print.
13. Nanus DM: Of peptides and peptidases: the role of cell surface peptidases in cancer. Clin Cancer Res 2003; 9: 6307-6309. (Pubitemid 38031813)
14. Bagnato A, Rosano L: The endothelin axis in cancer. Int J Biochem Cell Biol 2008; 40: 1443-1451.
15. Banerjee S, Hussain M, Wang Z, Saliganan A, Che M, Bonfil D, Cher M, Sarkar FH: In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer Res 2007; 67: 3818-3826. (Pubitemid 46762169)
16. Ross JS, Kallakury BVS, Sheehan CE, Fisher HA, Kaufman RP Jr, Kaur P, Gray K, Strin ger B: Expression of nuclear factor-kappa B and I kappa B alpha proteins in prostatic adenocarcinomas: correlation of nuclear factorkappa B immunoreactivity with disease recurrence. Clin Cancer Res 2004; 10: 2466-2472. (Pubitemid 38445708)
17. Lessard L, Mes-Masson A-M, Lamarre L, Wall L, Lattouf JB, Saad F: NF-kappa B nuclear localization and its prognostic significance in prostate cancer. Br J Urol Int 2003; 91: 417-420. (Pubitemid 36359653)
18. Fradet V, Lessard L, Begin LR, Karakiewicz P, Masson AM, Saad F: Nuclear factor-kappaB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer. Clin Cancer Res 2004; 10: 8460-8464. (Pubitemid 40053410)
19. Lessard L, Karakiewicz PI, Bellon-Gagnon P, Alam-Fahmy M, Ismail HA, Mes-Masson AM, Saad F: Nuclear localization of nuclear factor-kappaB p65 in primary prostate tumors is highly predictive of pelvic lymph node metastases. Clin Cancer Res 2006; 12: 5741-5745. (Pubitemid 44629604)
20. Freedland SJ, Seligson DB, Liu AY, Pantuck AJ, Paik SH, Horvath S, Wieder JA, Zisman A, Nguyen D, Tso CL, Palotie AV, Belldegrun AS: Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer. Prostate 2003; 55: 71-80. (Pubitemid 36397747)
21. Usmani BA, Shen R, Janeczko M, Papandreou CN, Lee WH, Nelson WG, Nelson JB, Nanus DM: Methylation of the neutral endopeptidase gene promoter in human prostate cancers. Clin Cancer Res 2000; 6: 1664-1670. (Pubitemid 30305058)
22. Osman I, Dai J, Mikhail M, Navarro D, Taneja SS, Lee P, Christos P, Shen R, Nanus DM: Loss of neutral endopeptidase and activation of protein kinase B (Akt) is associated with prostate cancer progression. Cancer 2006; 107: 2628-2636. (Pubitemid 44845618)
23. Patrikidou A, Vlachostergios PJ, Voutsadakis IA Hatzidaki E, Valeri RM, Destouni C, Apostolou E, Daliani D, Papandreou CN: Inverse baseline expression pattern of the NEP/neuropeptides and NFkappaB/proteasome pathways in androgen-dependent and androgen-independent prostate cancer cells. Cancer Cell Int 2011; 11: 13.